Evolus Q1 revenue up 42% YoY to $59.3M; on track for non-GAAP profitability in Q4 2024

Evolus, Inc.

2024-Q1 EPS reported -$0.22 revenue$59,333,000

Net revenue $59.3M (+42% YoY); gross margin 68.3%; non-GAAP loss from ops $0.9M, narrowing from Q4 2023's $3.7M.
Reaffirms FY2024 revenue guidance of $255-265M; expects non-GAAP profitability in Q4 2024 and full-year 2025.
FDA submission for Evolysse dermal fillers within 90 days; expanding into Australia and Spain with Nuceiva.
Added 700+ new customer accounts; reorder rate ~70%; Evolus Rewards members ~825,000.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Evolus, Inc. reported the first quarter ended March 31, 2024 results: revenue $59.3 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2024
Revenue: $59.3 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total net revenues for the first quarter of 2024 increased 42% to $59.3 million from $41.7 million in the first quarter of 2023

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Evolus, Inc. filing history →

Source: SEC EDGAR

accession 0001570562-24-000078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.